期刊文献+

Graves病固定剂量与个体化剂量^(131)I治疗的临床研究 被引量:1

Clinical Study of ^(131)I Treatment of Fixed Dose and Individual Dose for Graves Disease
下载PDF
导出
摘要 目的:研究比较固定剂量与个体化剂量131I治疗Graves病的临床效果,以及并发生症的发生情况。方法:选取笔者所在医院2014年3月-2015年3月收治的Graves患者300例,随机分为对照组与研究组,其中对照组采用固定剂量131I进行治疗,研究组采用个体化剂量131I进行治疗,随访6个月,比较两组患者的临床疗效以及并发症发生率。结果:治疗后对照组总有效率80.67%,研究组79.33%,两组比较差异无统计学意义(P>0.05)。对照组甲减发生率48.67%,研究组发生率33.33%,两组比较差异有统计学意义(P<0.05)。结论:Graves病采用固定化剂量和个体化剂量131I临床疗效均显著,个体化剂量甲减发生率低,安全性更高,值得临床广泛推广应用。 Objective:To study the clinical effect of 131 I treatment for Graves disease of fixed dose and individual dose,and the incidence condition of complications.Method:From March 2014 to March 2015,300 cases with Graves in our hospital were selected,and they were divided them into the control group and the research group.The control group was treated with the fixed dose 131 I treatment,while the study group was treated with individual dose 131 I treatment.And then they were followed up for 6 months,the clinical efficacy and complications incidence rate of the two groups were compared.Result:After treatment,the total effective rate of the control group was 80.67%,while the research group was 79.33%,and the difference between the two groups showed no statistically significant(P〈0.05).However,the incidence of hypothyroidism in the control group was 48.67%,while the research group was 33.33%,and the difference between the two groups was statistically significant(P〈0.05).Conclusion:The clinical efficacy of the fixed dose and individual dose 131 I treatment for Graves disease are very significant,but the individual dose treatment has a low incidence rate of hypothyroidism.Benefit from the higher security,the individual dose 131 I treatment is worthy of clinical popularization and application.
出处 《中外医学研究》 2016年第17期3-4,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 GRAVES病 固定剂量 个体化剂量 131I Graves disease Fixed dose Individual dose 131I
  • 相关文献

参考文献6

二级参考文献35

  • 1徐海滨.不同剂量碘-131首次治疗甲亢疗效对比研究[J].医学信息(医学与计算机应用),2014,0(29):187-187. 被引量:3
  • 2Acharya S H, Avenell A, Philip S, et al. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy : a systematic review[J]. Clin Endocrinol (Oxf) , 2008, 69(6) : 943 -950.
  • 3Collier A, Ghosh S, Hair M, et al. Comparison of two fixed activities of radioiodine therapy (370vs. 555 MBq) in patients with Graves disease[J]. Hormones (Athens), 2009, 8(4): 273-278.
  • 4Neto A M, Tambascia M A, Brunetto S, et al. Extremely high doses of radioiodine required for treatment of Graves' hyperthyroidism: a case report[J]. Cases J, 2009, 2: 8479.
  • 5Kita T, Yokoyama K, Kinuya S, et al. Single dose planning for radioiodine-131 therapy of Graves disease [ J ]. Ann Nucl Med, 2004, 18 (2) : 151 -155.
  • 6El-Kaissi S, Bowden J, Henry M J, et al. Association between radioiodine therapy for Graves'hyperthyroidism and thyroid-associated ophthalmopathy[J]. Int Ophthalmol, 2010, 30(4) : 397 -405.
  • 7Alfadda A, Malabu U H, El-Desouki M I, et al. Treatment of Graves' hyperthyroidism - prognostic factors for outcome [ J ]. Saudi Med J, 2007, 28(2): 225-230.
  • 8Bogazzi F, Giovannetti C, Fessehatsion R, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal[ J ]. J Clin Endocrinol Metab, 2010, 95 ( 1 ) : 201 - 208.
  • 9Isgoren S, Daglioz-Gorur G, Demir H, et al. Radioiodine therapy in Graves' disease: Is it possible to predict outcome before therapy? [J]. Nucl Med Commun. 2012, 33(8) : 859 -863.
  • 10中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:858

共引文献41

同被引文献6

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部